Retavibart

芮特韦拜单抗

Report date: 2026/03/06 20:02:51

Base Information

Drug NameRetavibart
Drug Alias NameTNM-001
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionRespiratory syncytial virus F protein inhibitors
TargetsRespiratory syncytial virus F protein
Therapy Area/IndicationsLower Respiratory Tract InfectionsRespiratory Syncytial Virus Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusNDA/BLA
Highest Status in ChinaNDA/BLA
Originator CompaniesZhuhai Trinomab Pharmaceutical Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesZhuhai Trinomab Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsLower Respiratory Tract InfectionsRespiratory Syncytial Virus Infections
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A